CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II

Summary

To explore the efficacy and safety of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes

Conditions

• Stroke

Interventions

DRUG

Tenecteplase

Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)

DRUG

The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)

Best treatment arm

Sponsors & Collaborators

• Puer People's Hospital

  collaborator UNKNOWN

• Shanghai 6th People's Hospital

  collaborator OTHER

• Hexigten Traditional Chinese and Mongolian Medicine Hospital

  collaborator UNKNOWN

• Yangpu Hospital, School of Medicine, Tongji University

  collaborator UNKNOWN

• The First Affiliated Hospital of Shanxi Medical University

  collaborator OTHER

• Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine

  collaborator UNKNOWN

• Linyi People's Hospital

  collaborator OTHER

• Shanghai 10th People's Hospital

  collaborator OTHER

• Nanshi Hospital of Nanyang

  collaborator UNKNOWN

• Fudan University

  collaborator OTHER

• Xuzhou Medical University Affiliated Hospital of Huaian

  collaborator UNKNOWN

• Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

  collaborator UNKNOWN

• The First Affiliated Hospital of Soochow Medical University

  collaborator UNKNOWN

• Affiliated Haian People's Hospital of Nantong University

  collaborator UNKNOWN

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• the Third Hospital of Mianyang

  collaborator UNKNOWN

• Zhejiang Province People's Hospital

  collaborator UNKNOWN

• Shanghai East Hospital

  collaborator OTHER

• The Central Hospital of Jiaozuo Coal Group

  collaborator UNKNOWN

• Huizhou Municipal Central Hospital

  collaborator OTHER

• Zhejiang University

  collaborator OTHER

• The Second Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• Ningbo No. 1 Hospital

  collaborator OTHER

• Huashan Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-09-28

Primary Completion

2023-09-30

Completion

2023-09-30

Countries

• China

Study Locations